Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

被引:24
|
作者
Cummins, Kathleen A. [1 ]
Russell, Gregory B. [2 ]
Votanopoulos, Konstantinos I. [1 ]
Shen, Perry [1 ]
Stewart, John H. [1 ]
Levine, Edward A. [1 ]
机构
[1] Wake Forest Baptist Hlth, Dept Gen Surg, Sect Surg Oncol, Winston Salem, NC USA
[2] Wake Forest Baptist Hlth, Dept Biostat Sci, Winston Salem, NC USA
关键词
Pseudomyxoma peritonei (PMP); appendiceal neoplasms; cytoreduction surgical procedures; regional perfusion antineoplastic chemotherapy;
D O I
10.3978/j.issn.2078-6891.2015.101
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown variability in survival outcomes when used to treat peritoneal surface disease (PSD) from appendiceal and colorectal cancers. The primary goal of this study was to examine outcomes for high-grade appendiceal (HGA) and high-grade colonic primaries after CRS-HIPEC to determine if a significant difference exists between the two groups. Methods: A retrospective analysis of patients with peritoneal dissemination from appendiceal and colonic primaries were identified in a prospectively maintained database of 1,223 CRS-HIPEC procedures performed between 1991 and 2015. Patient demographics, performance status resection status, tumor grade, nodal status, morbidity, mortality, and survival were reviewed with biopsy-proven PSD being classified according to primary site. Univariate and multivariate analyses were performed, and outcomes compared. Results: The study identified 171 CRS-HIPEC procedures for 165 patients: 110 (66.7%) for HGA and 55 (33.3%) for high-grade colonic lesions. Observed median disease-free survival (DFS) and overall survival (OS) for both groups were the same at14.4 and 18 months, respectively. Median survival according to resection status for R0/R1, R2a, and R2b/c were 36, 15.6, and 8.4 months (P<0.0001). Median OS for those who received preoperative chemotherapy versus those who did not were 14.4 and 20.4 months, respectively (P=0.01). For those who received preoperative chemotherapy, no difference was apparent in the DFS interval (P=0.34). Multivariate predictors of OS included resection status (P<0.0001) and lymph node involvement (P=0.0005). Conclusions: Preoperative chemotherapy offered no clear DFS or OS benefit, for HGA or high-grade colon cancer patients. Complete cytoreduction offered the greatest survival benefit to both groups with a correlating drop in survival to resection status. Outcomes for high grade appendiceal cancer are remarkably similar to colon cancer.
引用
收藏
页码:3 / 9
页数:7
相关论文
共 50 条
  • [1] Analysis of feasibility and survival in repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in appendiceal cancer with peritoneal dissemination.
    Karpes, Josh
    Parikh, Roneil
    Shamavonian, Raphael
    Alzahrani, Nayef
    Morris, David L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Overall Survival after Systemic Chemotherapy in Patients with High-Grade Appendiceal Cancer Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Nagarajan, Bharath
    Singh, Jaiveer
    Gelli, Ashita
    Lenin, Jayarani
    Prabhu, Selva
    Sundaramurthi, Sudharsanan
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2022, 26 (12) : 2628 - 2629
  • [3] Overall Survival after Systemic Chemotherapy in Patients with High-Grade Appendiceal Cancer Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Bharath Nagarajan
    Jaiveer Singh
    Ashita Gelli
    Jayarani Lenin
    Selva Prabhu
    Sudharsanan Sundaramurthi
    [J]. Journal of Gastrointestinal Surgery, 2022, 26 : 2628 - 2629
  • [4] ASO Visual Abstract: Systemic Chemotherapy in High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread after Unsuccessful Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Baron, Ekaterina
    Sardi, Armando
    King, Mary Caitlin
    Nikiforchin, Andrei
    Lopez-Ramirez, Felipe
    Nieroda, Carol
    Gushchin, Vadim
    Ledakis, Panayotis
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (11) : 6592 - 6592
  • [5] ASO Visual Abstract: Systemic Chemotherapy in High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread after Unsuccessful Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Ekaterina Baron
    Armando Sardi
    Mary Caitlin King
    Andrei Nikiforchin
    Felipe Lopez-Ramirez
    Carol Nieroda
    Vadim Gushchin
    Panayotis Ledakis
    [J]. Annals of Surgical Oncology, 2022, 29 : 6592 - 6592
  • [6] Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma
    Tan, Grace H. C.
    Cheung, Michelle
    Chanyaputhipong, Jendana
    Soo, Khee Chee
    Teo, Melissa C. C.
    [J]. ANNALS ACADEMY OF MEDICINE SINGAPORE, 2013, 42 (06) : 291 - 296
  • [7] Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoid Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Zambrano-Vera, K.
    Sardi, A.
    Studeman, K.
    Nieroda, C.
    Sittig, M.
    Munoz-Zuluaga, C. A.
    Sipok, A.
    Gushchin, V.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S111 - S111
  • [8] Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Zambrano-Vera, Katherin
    Sardi, Armando
    Munoz-Zuluaga, Carlos
    Studeman, Kimberley
    Nieroda, Carol
    Sittig, Michelle
    King, Mary Caitlin
    Sipok, Arkadii
    Gushchin, Vadim
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (01) : 179 - 187
  • [9] Outcomes in Peritoneal Carcinomatosis from Appendiceal Goblet Cell Carcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
    Katherin Zambrano-Vera
    Armando Sardi
    Carlos Munoz-Zuluaga
    Kimberley Studeman
    Carol Nieroda
    Michelle Sittig
    Mary Caitlin King
    Arkadii Sipok
    Vadim Gushchin
    [J]. Annals of Surgical Oncology, 2020, 27 : 179 - 187
  • [10] Peritoneal mestastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
    Falla-Zuniga, Luis Felipe
    Sardi, Armando
    King, Mary Caitlin
    Lopez-Ramirez, Felipe
    Barakat, Philipp
    Nieroda, Carol
    Diaz-Montes, Teresa
    Gushchin, Vadim
    [J]. PLEURA AND PERITONEUM, 2024, 9 (01) : 15 - 22